|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Reduction in the size of a uterine leiomyoma following discontinuation of an |
| estrogen-progestin contraceptive. |
| GYNECOLOGIC AND OBSTETRIC INVESTIGATION. 1997;43(4):276-7. |
| Although estrogen and progestin influence the volume of uterine leiomyomas, these effects have not been well |
| characterized. Presented is the case of a 45-year-old US woman with right lower quadrant pain and a 5-year history of |
| use of a combined oral contraceptive (OC) containing 0.35 mcg ethinyl estradiol and 0.35 mcg norgestrel. At |
| presentation, the uterus was enlarged to a size corresponding to 12-14 gestational weeks, with a mass at the right |
| fundal margin. Pelvic ultrasonography revealed a large dominant leiomyoma 7.2 x 5.8 x 5.5 cm and several smaller |
| tumors. OC use was discontinued and, 4 months later, the uterus was a size of 8-10 gestational weeks and a single |
| serosal leiomyoma 5.9 x 4.6 x 4.4 cm remained. The leiomyoma volume had decreased by 47% after OC |
| discontinuation, to 63 cu. cm. Pelvic sonography 12 months after OC discontinuation revealed no further changes in |
| myoma volume. In OC users with clinically significant uterine leiomyomas, discontinuation of combined OCs should |
| be considered as a low-risk intervention with the potential to decrease uterine volume. (PubHealth.info Document ID: |
| PubHealth.info NOTE: The author(s) of this article titled, "Reduction in the size of a uterine leiomyoma following |
| discontinuation of an estrogen-progestin contraceptive.", is(are) Barbieri RL. The source of this article is |
| "GYNECOLOGIC AND OBSTETRIC INVESTIGATION. 1997;43(4):276-7.". This article was published in 1997 in |
| English language(s). (PubHealth.info® Document ID: CONT2T 1039-06. All rights reserved with PubHealth.info) PIN: |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |